Relay Therapeutics Inc. Common Stock vs Telus Corporation Ordinary Shares — how do they compare? Relay Therapeutics Inc. Common Stock trades at $17.07 (market cap $3.81B), while Telus Corporation Ordinary Shares trades at $8.11 (market cap $12.52B). The key difference: Telus Corporation Ordinary Shares is far larger — about 3.3× Relay Therapeutics Inc. Common Stock's market cap, and Telus Corporation Ordinary Shares pays a 6.59% dividend while Relay Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Relay Therapeutics Inc. Common Stock for 5 Days and Telus Corporation Ordinary Shares for 0 Days on average.
| RLAY | TU | |
|---|---|---|
Market Cap | $3.81B | $12.52B |
Volume | 1,706,150 | 6,655,034 |
Sector | Health | Media |
52-Week High | $20.75 | $15.33 |
52-Week Low | $6.05 | $7.72 |
Typical Hold Time | 5 Days | 0 Days |
Enterprise Value | $2.93B | $33.57B |
Dividend Yield | — | 6.59% |
Signals from Pluang's Aura AI — not financial advice
Relay Therapeutics (RLAY) trades at $17.36, down 3.45% today, with technical indicators showing bearish momentum. The company remains in clinical-stage development with negative profitability metrics, including a -2,763.64% net income margin and -$276.48M net loss for 2025. Recent Q2 2026 earnings missed expectations with a loss of $0.41 per share, though the company continues advancing its oncology pipeline with Phase 3 trials planned for 2027.
Despite unanimous analyst buy ratings and a $26.25 consensus price target representing 51% upside, RLAY faces significant execution risk as a pre-revenue biotech. The stock's bearish technical setup and persistent cash burn require careful risk management, though institutional accumulation and AI-driven drug discovery platform provide long-term potential.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →Telus Corporation is a Canadian telecommunications company providing wireless, internet, television, and business connectivity services, with additional operations in digital healthcare through Telus Health and customer experience services through Telus Digital.
Read more on TU →